|
ABCD nationwide
audit programme in the future
ABCD has learned from its
previous ABCD
nationwide audits of GLP1 receptor agonists, SGLT2 inhibitors,
insulin degludec, IDegLira and most recently the FreeStyle Libre. It has
learned the best ways of undertaking successful nationwide audits. It
has also realised how much clinically useful information can be obtained
from the audit information to improve patient care. We are constantly
considering possible future nationwide audits, both of new diabetes
therapies and of devices. 2020 should see the launch of an audit of testosterone in men
with type two diabetes and of an audit of Do-It-Yourself Artificial
Pancreas system and, in due course, of commercially available closed
loop systems. |
